TSLA
Tesla
-- 462.280 NVDA
NVIDIA
-- 140.220 AMD
Advanced Micro Devices
-- 126.290 PLTR
Palantir
-- 82.380 MSTR
MicroStrategy
-- 358.180 
NEWS
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon presented new Phase 2 datafor ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Key findings include:
- 0% of ANX007 monthly-treated patients with less advanced disease lost 15 letters vs. 17% of sham patients
- 6% of ANX007 monthly-treated overall patients lost 15 letters vs. 21% of sham overall patients
- 61% decrease in EZ loss between ANX007 and sham in patients with <80% EZ loss at baseline
- 48% decrease in EZ loss between ANX007 and sham in patients with <98% EZ loss at baseline
These results highlight ANX007's potential for earlier intervention in dry AMD and GA. Pivotal Phase 3 ARCHER II data is expected in the second half of 2026.
- 0% of ANX007 monthly-treated patients with less advanced disease lost 15 letters vs. 17% of sham patients
- 6% of ANX007 monthly-treated overall patients lost 15 letters vs. 21% of sham overall patients
- 61% decrease in EZ loss between ANX007 and sham in patients with <80% EZ loss at baseline
- 48% decrease in EZ loss between ANX007 and sham in patients with <98% EZ loss at baseline
These results highlight ANX007's potential for earlier intervention in dry AMD and GA. Pivotal Phase 3 ARCHER II data is expected in the second half of 2026.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment